These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23402735)

  • 21. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Bocan TM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypercholesterolemia: chemical aspect of approach.
    Salakhutdinov NF; Rogoza LN; Tolstikov GA
    Curr Med Chem; 2011; 18(26):4076-105. PubMed ID: 21824085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pitavastatin - a novel therapeutic milestone.
    Ohbayashi H
    Drugs Today (Barc); 2010 Oct; 46(10):765-75. PubMed ID: 21076713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early vascular benefits of statin therapy.
    Tsiara S; Elisaf M; Mikhailidis DP
    Curr Med Res Opin; 2003; 19(6):540-56. PubMed ID: 14594527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanisms of statin nephroprotective actions].
    Chmielewski M; Zdrojewski Z; Rutkowski B
    Przegl Lek; 2002; 59(7):519-22. PubMed ID: 12516241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol-lowering with statins: are they all the same? - Summary of the Expert Symposium at the 53rd Annual Scientific Sessions of the American College of Cardiology.
    International Task Force for the Prevention of Coronary Heart Disease
    Timely Top Med Cardiovasc Dis; 2004 Sep; 8():E8. PubMed ID: 15543260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory and immunomodulatory effects of statins.
    Blanco-Colio LM; Tuñón J; Martín-Ventura JL; Egido J
    Kidney Int; 2003 Jan; 63(1):12-23. PubMed ID: 12472764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).
    Oliveira EF; Santos-Martins D; Ribeiro AM; Brás NF; Cerqueira NS; Sousa SF; Ramos MJ; Fernandes PA
    Expert Opin Ther Pat; 2016 Nov; 26(11):1257-1272. PubMed ID: 27537201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesterol-lowering with statins: are they all the same? Summary of the expert symposium at the 53rd Annual Scientific Sessions of the American College of Cardiology.
    International Task Force for the Prevention of Coronary Heart Disease
    Drugs Today (Barc); 2004 Jun; 40(6):555-61. PubMed ID: 15349133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors.
    Chong PH
    Ann Pharmacother; 2002 Dec; 36(12):1907-17. PubMed ID: 12452755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are statins effective for simultaneously treating dyslipidemias and hypertension?
    Koh KK; Quon MJ; Waclawiw MA
    Atherosclerosis; 2008 Jan; 196(1):1-8. PubMed ID: 17662294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
    Davidson MH
    Drugs; 2001; 61(2):197-206. PubMed ID: 11270938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
    Stalenhoef AF; Stehouwer CD
    Ned Tijdschr Geneeskd; 2000 Feb; 144(7):308-10. PubMed ID: 10707739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins and cardioprotection--more than just lipid lowering?
    Ludman A; Venugopal V; Yellon DM; Hausenloy DJ
    Pharmacol Ther; 2009 Apr; 122(1):30-43. PubMed ID: 19318042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and stroke.
    Endres M
    J Cereb Blood Flow Metab; 2005 Sep; 25(9):1093-110. PubMed ID: 15815580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins: potential new indications in inflammatory conditions.
    Endres M
    Atheroscler Suppl; 2006 Apr; 7(1):31-5. PubMed ID: 16503422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.